omalizumab, Xolair (cont.)
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
GENERIC AVAILABLE: No PREPARATIONS: Sterile powder for Injection: 5 ml vial (150 mg)
STORAGE: Omalizumab should be refrigerated between 2 C to 8 C (36 F to 46 F). When mixed with sterile water, the solution should be used within 8 hours if refrigerated between 2 C to8 C (36 F to 46 F) or within 4 hours if stored at room temperature.
PRESCRIBED FOR: Omalizumab is used for treating adolescents and adults 12 years and older who have allergy sensitive, moderate to severe persistent asthma, that is not adequately controlled with inhaled steroids.
DOSING: Omalizumab is injected under the skin. The recommended dose is 150-375 mg every 2 to 4 weeks. The dose and frequency is based on body weight and levels of serum IgE, a type of antibody that is important in promoting some types of allergic reactions. Doses greater than 150 mg should be divided and administered at different sites so that no more than 150 mg is administered at each injection site.
DRUG INTERACTIONS: Drug interaction studies have not been conducted with omalizumab.
PREGNANCY: Omalizumab has not been adequately studied in pregnant women.
NURSING MOTHERS: Use of omalizumab by nursing mothers has not been adequately evaluated. Since antibodies similar to omalizumab are excreted in human breast milk, it is likely that omalizumab also is excreted in breast milk.
SIDE EFFECTS: The most common side effects observed in patients treated with omalizumab are headaches, viral infections, upper respiratory tract infections, and injection-site reactions such as pain, redness, swelling, itching and bruising. Use of omalizumab may also lead to serious, life-threatening allergic reactions (anaphylaxis) which manifest as bronchospasm with difficulty breathing, fainting, low blood pressure, and swelling of the tongue or throat. It is recommended that patients be observed for these reactions for at least two hours after injection of omalizumab; however, these reactions can occur up to 24 hours or longer after the injections, and they have occurred even after one year of regular treatment. Since allergic reactions can occur after any dose, patients should carry medications for emergency self-treatment. In clinical trials cancer occurred more frequently in patients who took omalizumab.
Reference: FDA Prescribing Information
Last Editorial Review: 9/5/2012
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index